Physician profile
Quentin L Vanmeter
NPI 1245265453
$214,915.97
in general payments reported to CMS, 2019-2025
50 companies · $52K in 2025
The $52K reported for 2025 was more than what 97% of Pediatric Endocrinology providers received nationally (typical 2025 total: $294).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $2,485 · 2020: $9,233 · 2021: $17K · 2022: $60K · 2023: $21K · 2024: $53K · 2025: $52K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $89K · Consulting Fee: $16K · Food and Beverage: $12K · Travel and Lodging: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $88,865.26 |
| Consulting Fee | $15,699.49 |
| Food and Beverage | $11,845.69 |
| Travel and Lodging | $10,119.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $134,059.46 | 2020-2025 | Sogroya, Wegovy, Norditropin |
| Sanofi-Aventis U.S. LLC | $42,828.98 | 2023-2025 | |
| Eton Pharmaceuticals, INC. | $12,782.98 | 2020-2025 | Alkindi, Increlex, Khindivi |
| Tolmar Pharmaceuticals, INC. | $5,453.93 | 2020-2022 | |
| Azurity Pharmaceuticals, INC. | $5,214.31 | 2023-2025 | Triptodur, Triptodur, Adthyza |
| Abbvie INC. | $2,351.25 | 2019-2025 | Lupron Depot, Synthroid |
| Pfizer INC. | $1,661.84 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $1,553.19 | 2019-2025 | Strensiq |
| Eli Lilly and Company | $1,136.18 | 2019-2021 | |
| Insulet Corporation | $865.63 | 2019-2024 | Omnipod |
| Xeris Pharmaceuticals, INC. | $720.76 | 2020-2024 | Gvoke Hypopen |
| Ascendis Pharma Endocrinology INC | $605.10 | 2022-2025 | Skytrofa |
| Beta Bionics, INC. | $557.53 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Sequel Med Tech, LLC | $445.69 | 2025 | Twiist |
| Tandem Diabetes Care, INC. | $413.69 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $358.67 | 2021-2025 | Minimed 780g |
| Endo Pharmaceuticals INC. | $312.55 | 2019-2023 | Supprelin |
| Tolmar, INC. | $243.10 | 2023-2025 | Fensolvi |
| Zealand Pharma US, INC. | $237.01 | 2021-2022 | |
| Dexcom, INC. | $225.73 | 2020-2023 | Dexcom G6 Transmitter |
| Ultragenyx Pharmaceutical INC. | $221.04 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $210.46 | 2019-2021 | |
| Ibsa Pharma INC. | $189.93 | 2019-2024 | Licart, Tirosint |
| Companion Medical, INC. | $182.93 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $167.42 | 2021-2025 | Unithroid |
| Neurocrine Biosciences, INC. | $158.40 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $153.46 | 2019-2020 | |
| Kyowa Kirin, INC. | $152.70 | 2023-2025 | Crysvita, Crysvita |
| Bigfoot Biomedical INC | $151.50 | 2022 | |
| Lilly USA, LLC | $150.88 | 2020-2024 | Jardiance, Trulicity, Mounjaro |
| Arbor Pharmaceuticals, INC. | $127.08 | 2019-2021 | |
| Amphastar Pharmaceuticals, INC. | $125.70 | 2024-2025 | |
| Amryt Pharma Holdings Ltd | $125.56 | 2021 | |
| Biomarin Pharmaceutical INC. | $88.98 | 2021-2025 | Voxzogo 1.2mg |
| Abbott Laboratories | $75.35 | 2019-2025 | Freestyle Libre 3 |
| Kvk-Tech, INC. | $74.70 | 2025 | |
| Rhythm Pharmaceuticals, INC. | $70.89 | 2023-2025 | Imcivree, Imcivree |
| Mannkind Corporation | $66.73 | 2021-2022 | |
| Embecta Corp. | $63.91 | 2024 | Bd Nano 2nd Gen Pen Needle |
| Sandoz INC. | $60.62 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.59 | 2022-2025 | Jardiance |
| Endo USA, INC. | $51.68 | 2024-2025 | Supprelin |
| Soleno Therapeutics, INC. | $47.59 | 2025 | Vykat Xr |
| Corcept Therapeutics | $41.51 | 2022-2024 | Korlym |
| Amgen INC. | $30.00 | 2024 | Evenity |
| Becton, Dickinson and Company | $25.57 | 2022 | |
| Medtronic Minimed, INC. | $15.21 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$16,785.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Quentin Vanmeter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.